药学学报, 2018, 53(10): 1591-1597
引用本文:
唐晓楠, 张海婧, 王文杰, 吴练秋. 靶向JAK治疗自身免疫病的小分子药物研究进展[J]. 药学学报, 2018, 53(10): 1591-1597.
TANG Xiao-nan, ZHANG Hai-jing, WANG Wen-jie, WU Lian-qiu. Research progress of small-molecule drugs targeting JAK in autoimmune diseases[J]. Acta Pharmaceutica Sinica, 2018, 53(10): 1591-1597.

靶向JAK治疗自身免疫病的小分子药物研究进展
唐晓楠, 张海婧, 王文杰, 吴练秋
中国医学科学院、北京协和医学院药物研究所, 北京 100050
摘要:
自身免疫病是指机体对自身抗原发生免疫反应导致自体组织损伤所引起的一系列疾病,通常包括类风湿关节炎(RA)、系统性红斑狼疮(SLE)和银屑病等。JAKs(Janus kinases)为一类非受体型酪氨酸激酶,是调控许多炎性细胞因子合成及释放所必需的信号转导介质,而这些炎性因子与自身免疫病的发生和发展密切相关。研究表明靶向JAK小分子抑制剂可通过调节炎性因子的信号转导通路而发挥其抗炎和免疫调节的药理学活性。本文对近年来在研及上市靶向JAK治疗自身免疫病的小分子药物进行梳理和归纳,旨在为该类药物的进一步研发提供参考。
关键词:    JAK      JAK/STAT      小分子药物      自身免疫病     
Research progress of small-molecule drugs targeting JAK in autoimmune diseases
TANG Xiao-nan, ZHANG Hai-jing, WANG Wen-jie, WU Lian-qiu
Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
Abstract:
Autoimmune disease refers to a series of diseases caused by the body's immune response to autoantigens leading to autologous tissue damage. The examples include rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and psoriasis, etc. Janus kinases (JAKs) are a class of non-receptor tyrosine kinases that are essential signaling mediators in the signal transduction and expression of the inflammatory cytokines, which are closely related to the occurrence and development of the autoimmune diseases. Studies have shown that the inhibitors targeting JAK can exert anti-inflammatory and immuno-modulatory pharmacological activities by modulation of the cell signaling pathways related to the inflammatory cytokines. In this paper, the literature about small-molecule drugs targeting JAK on autoimmune diseases in recent years are summarized to provide valuable information for the research and development of drugs.
Key words:    JAK    JAK/STAT    small-molecule drug    autoimmune disease   
收稿日期: 2018-03-30
DOI: 10.16438/j.0513-4870.2018-0281
基金项目: 北京市自然科学基金面上项目(7172139);中国医学科学院医学与健康科技创新工程项目(2016-12M-3-011).
通讯作者: 吴练秋,Tel:86-10-63031589,E-mail:wlq@imm.ac.cn
Email: wlq@imm.ac.cn
相关功能
PDF(245KB) Free
打印本文
0
作者相关文章
唐晓楠  在本刊中的所有文章
张海婧  在本刊中的所有文章
王文杰  在本刊中的所有文章
吴练秋  在本刊中的所有文章

参考文献:
[1] Wahren-Herlenius M, Dörner T. Immunopathogenic mechanisms of systemic autoimmune disease[J]. Lancet, 2013, 382:819-831.
[2] Clark JD, Flanagan M, Telliez JB. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases[J]. J Med Chem, 2014, 57:5023-5038.
[3] Saharinen P, Takaluoma K, Silvennoinen O, et al. Regulation of the Jak2 tyrosine kinase by its pseudokinase domain[J]. Mol Cell Biol, 2000, 20:3387-3395.
[4] Chaturvedi P, Sharma S, Reddy EP, et al. Abrogation of interleukin-3 dependence of myeloid cells by the v-src oncogene requires SH2 and SH3 domains which specify activation of STATs[J]. Mol Cell Biol, 1997, 17:3295-3304.
[5] Coskun M, Salem M, Pedersen J, et al. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease[J]. Pharmacol Res, 2013, 76:1-8.
[6] Calabrese LH, Rose-John S. IL-6 biology:implications for clinical targeting in rheumatic disease[J]. Nat Rev Rheumatol, 2014, 10:720-727.
[7] Gao W, McGarry T, Orr C, et al. Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors[J]. Ann Rheum Dis, 2016, 75:311-315.
[8] Dhillon S. Tofacitinib:a review in rheumatoid arthritis[J]. Drugs, 2017, 77:1987-2001.
[9] Lee EB1, Fleischmann R, Hall S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis[J]. N Engl J Med, 2014, 370:2377-2386.
[10] Naganuma M, Mizuno S, Nanki K, et al. Recent trends and future directions for the medical treatment of ulcerative colitis[J]. Clin J Gastroenterol, 2016, 9:329-336.
[11] Markham A. Baricitinib:first global approval[J]. Drugs, 2017, 77:697-704.
[12] Genovese MC, Kremer J, Zamani O, et al. Baricitinib in patients with refractory rheumatoid arthritis[J]. N Engl J Med, 2016, 374:1243-1252.
[13] Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis[J]. N Engl J Med, 2017, 376:652-662.
[14] Cao YJ, Sawamoto T, Valluri U, et al. Pharmacokinetics, pharmacodynamics, and safety of ASP015K (peficitinib), a New Janus kinase inhibitor, in healthy subjects[J]. Clin Pharmacol Drug Dev, 2016, 5:435-449.
[15] Ito M, Yamazaki S, Yamagami K, et al. A novel JAK inhibitor, peficitinib, demonstrates potent efficacy in a rat adjuvant-induced arthritis model[J]. J Pharmacol Sci, 2017, 133:25-33.
[16] Nielsen OH, Seidelin JB, Ainsworth M, et al. Will novel oral formulations change the management of inflammatory bowel disease?[J]. Expert Opin Investig Drugs, 2016, 25:709-718.
[17] Banfield C, Scaramozza M, Zhang W, et al. The safety, tolerability, pharmacokinetics, and pharmacodynamics of a TYK2/JAK1 inhibitor (PF-06700841) in healthy subjects and patients with plaque psoriasis[J]. J Clin Pharmacol, 2018, 54:434-447.
[18] Dymock BW, Yang EG, Chu-Farseeva Y, et al. Selective JAK inhibitors[J]. Future Med Chem, 2014, 6:1439-1471.
[19] Ludbrook VJ, Hicks KJ, Hanrott KE, et al. Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase Ⅱa study[J]. Br J Dermatol, 2016, 174:985-995.
[20] Kahl L, Patel J, Layton M, et al. Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus[J]. Lupus, 2016, 25:1420-1430.
[21] Mohamed MF, Camp HS, Jiang P, et al. Pharmacokinetics, safety and tolerability of ABT-494, a novel selective JAK 1 inhibitor, in healthy volunteers and subjects with rheumatoid arthritis[J]. Clin Pharmacokinet, 2016, 55:1547-1558.
[22] Kremer JM, Emery P, Camp HS, et al. A phase Ⅱb study of ABT-494, a selective JAK-1 inhibitor, in patients with rheumatoid arthritis and an inadequate response to anti-tumor necrosis factor therapy[J]. Arthritis Rheumatol, 2016, 68:2867-2877.
[23] Yin Y, Zhang TT, Zhang DY. Research progress of JAK-3 kinase and its inhibitors[J]. Acta Pharm Sin (药学学报), 2016, 51:1520-1529.
[24] Farmer LJ, Ledeboer MW, Hoock T, et al. Discovery of VX-509(decernotinib):a potent and selective Janus kinase 3 inhibitor for the treatment of autoimmune diseases[J]. J Med Chem, 2015, 58:7195-7216.
[25] Gadina M, Schwartz DM, O'Shea JJ. Decernotinib:a next-generation jakinibs[J]. Arthritis Rheumatol, 2016, 68:31-34.
[26] Thorarensen A, Dowty ME, Banker ME, et al. Design of a Janus kinase 3(JAK3) specific inhibitor 1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl) prop-2-en-1-one (PF-06651600) allowing for the interrogation of JAK3 signaling in humans[J]. J Med Chem, 2017, 60:1971-1993.
[27] Coffey G, Betz A, DeGuzman F, et al. The novel kinase inhibitor PRT062070(cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer[J]. J Pharmacol Exp Ther, 2014, 351:538-548.
[28] Poulsen A, William A, Blanchard S, et al. Structure-based design of oxygen-linked macrocyclic kinase inhibitors:discovery of SB1518 and SB1578, potent inhibitors of Janus kinase 2(JAK2) and Fms-like tyrosine kinase-3(FLT3)[J]. J Comput Aided Mol Des, 2012, 26:437-450.
[29] Madan B, Goh KC, Hart S, et al. SB1578, a novel inhibitor of JAK2, FLT3, and c-Fms for the treatment of rheumatoid arthritis[J]. J Immunol, 2012, 189:4123-4134.
[30] Kettle JG, Åstrand A, Catley M, et al. Inhibitors of JAK-family kinases:an update on the patent literature 2013-2015, part 1[J]. Expert Opin Ther Pat, 2017, 27:127-143.
[31] Kettle JG, Åstrand A, Catley M, et al. Inhibitors of JAK-family kinases:an update on the patent literature 2013-2015, part 2[J]. Expert Opin Ther Pat, 2017, 27:145-161.
相关文献:
1.黄梅;戎煜;宁红秀;王春华;王银银;常智杰;.基于JAK/STAT信号通路的高通量药物筛选细胞模型的建立基于JAK/STAT信号通路的高通量药物筛选细胞模型的建立[J]. 药学学报, 2004,39(3): 164-167